Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

By A. Sistigu, T. Yamazaki, Erika Vacchelli, Kariman Chaba, D. Enot, J. Adam, Ilio Vitale, A. Goubar, E. Baracco, C. Remédios and 41 more. Nature Medicine, 2014

997 citations recorded by the source corpus.

Subfields: Immunology

View Paper: https://www.semanticscholar.org/paper/f618651dc8e23d69fb1a6f68fe3b7b85bb5d28b1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Guido Kroemer
2. L. Galluzzi
3. Lieping Chen
4. L. Zitvogel
5. J. Wolchok
6. W. Zou
7. D. Pardoll
8. Simone Fulda

Citations in the corpus

• Mitochondrial metabolism and cancer (2017, background): “That said, the release of mtDNA upon MOMP promotes the secretion of type I interferon (IFN) by malignant cells, and this is required for the activation of optimal anticancer immune responses upon chemotherapy and radiation therapy [202-205].”
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. (2015, background): “…are associated with decreased time-to-metastasis among patients with anthracycline-treated breast carcinoma (Apetoh et al., 2007; Ghiringhelli et al., 2009), whereas a type I IFN-related genetic signature correlates with clinical responses to this chemotherapeutic regimen (Sistigu et al., 2014).”
• PD-L1 (B7-H1) and PD-1 Pathway Blockade for Cancer Therapy: Mechanisms, Response Biomarkers and Combinations (2016, background): “Mouse studies suggest that therapeutic responses to some chemotherapy agents including anthracyclines and oxaliplatin may partially depend on immune responses, particularly type I IFN signaling–mediated immunity (156, 167).”
• The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer (2018, background): “Consistent with these in vitro findings, in vivo studies revealed that chemotherapy (Sistigu et al., 2014) and radiation treatment (Burnette et al., 2011; Lim et al., 2012; Deng et al., 2014) induce type I IFN signaling in tumors to promote antitumor immunity.”
• stLearn: integrating spatial location, tissue morphology and gene expression to find cell types, cell-cell interactions and spatial trajectories within undissociated tissues (2020, background): “Unlike observations from clade 1, the evolutionary progress in clade 2 was more likely to be driven by type I interferon 45 , with top upregulated genes including IFITM3, STAT1, IFI6, ISG15, IFI35, HLA-C, HLA-A, HLA-F, HLA-E identified.”